Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P00995

UPID:
ISK1_HUMAN

ALTERNATIVE NAMES:
Pancreatic secretory trypsin inhibitor; Tumor-associated trypsin inhibitor

ALTERNATIVE UPACC:
P00995

BACKGROUND:
The protein Serine protease inhibitor Kazal-type 1, with alternative names Pancreatic secretory trypsin inhibitor and Tumor-associated trypsin inhibitor, exhibits anti-trypsin activity in the pancreas and modulates sperm capacitance by inhibiting key processes in the male reproductive tract.

THERAPEUTIC SIGNIFICANCE:
Given its association with hereditary pancreatitis and tropical calcific pancreatitis, exploring the functions of Serine protease inhibitor Kazal-type 1 offers promising avenues for developing targeted treatments for these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.